KEY POINTS
- This case report describes a 31-year-old woman with left-sided ductal carcinoma in situ (DCIS) and a history of severe systemic lupus erythematosus (SLE). Her SLE had previously required intensive care but had remained in clinical remission for more than five years without immunosuppressive therapy. Rheumatological assessment confirmed no active symptoms, negative anti-dsDNA antibodies, normal complement levels, and preserved renal function. Following breast-conserving surgery and sentinel node biopsy, histopathology demonstrated 2.5-cm intermediate-grade DCIS (pTisN0M0) with negative margins, ER/PR negativity, and HER2 3+ expression.
- Adjuvant radiotherapy consisted of hypofractionated whole-breast irradiation with a sequential boost. VMAT delivered 42.56 Gy in 16 fractions, followed by 7.98 Gy in three fractions to the tumor bed, giving a total prescribed boost-region dose of 50.54 Gy in 19 fractions. Treatment incorporated deep inspiration breath-hold (DIBH), daily cone-beam CT verification, and a 5-mm PTV expansion restricted to 5 mm beneath the skin surface.
- DIBH reduced cardiac exposure compared with free-breathing planning. Mean heart dose decreased from 7.36 Gy to 5.81 Gy, while heart V25Gy declined from 8.98% to 5.79%. Mean left anterior descending coronary artery dose decreased from 29.68 Gy to 22.97 Gy, with a corresponding reduction in maximum LAD dose from 44.37 to 42.72 Gy. Target coverage remained similar, with PTV V95% of 99.96% during free breathing versus 99.85% with DIBH. Although DIBH improved dosimetry, the absolute residual cardiac exposure remains relevant in a young patient receiving adjuvant treatment for DCIS.
- The treatment strategy incorporated additional skin-sparing measures and prophylactic topical superoxide dismutase. The maximum skin dose was constrained to 53.57 Gy, approximately 106% of the cumulative prescription. A topical superoxide dismutase preparation was applied five times daily from the first fraction until two to three weeks after treatment completion. Because VMAT optimization, DIBH, skin constraints, and topical prophylaxis were used simultaneously, the independent contribution of superoxide dismutase cannot be determined.
- Acute treatment tolerance was favorable in this individual patient. Only RTOG grade 1 dermatitis, consisting of mild erythema and dry desquamation, developed during the third treatment week and began resolving within one week after irradiation. No grade ≥2 acute radiation toxicity was reported, and pain, fatigue, and cardiopulmonary adverse effects were documented as grade 0. Treatment was completed without interruption.
- Short-term follow-up showed no recurrence or clinically apparent late toxicity, but does not establish long-term safety. At ten months, the patient remained recurrence-free with favorable clinician-assessed cosmesis and no observed fibrosis, telangiectasia, or breast induration. Follow-up photography was unavailable. The single-patient design, sustained SLE remission, simultaneous protective interventions, and short follow-up prevent conclusions about radiation tolerance in patients with active lupus, late tissue injury, or the efficacy of topical superoxide dismutase.
CLINICAL TAKEAWAY
This case demonstrates that hypofractionated whole-breast irradiation can be completed with limited acute toxicity in a carefully selected patient with previously severe but clinically inactive systemic lupus erythematosus. However, one favorable outcome after ten months cannot establish long-term safety or validate prophylactic topical superoxide dismutase. Decisions regarding breast irradiation in patients with SLE should remain individualized according to current disease activity, anatomy, and expected treatment benefit.